Eliane Sardh

Publications
CV
Public outreach and news

Articles

Journal article: ORPHANET JOURNAL OF RARE DISEASES. 2024;19(1):365
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study
Sardh E; Balwani M; Rees DC; Anderson KE; Jia G; Sweetser MT; Wang B
Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2023;46(4):675-686
Maternal and fetal outcomes in acute hepatic porphyria: A Swedish National Cohort Study
Mantel A; Vassiliou D; Lissing M; Stephansson O; Wahlin S; Sardh E
Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2023;46(2):286-299
Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals
Lissing M; Vassiliou D; Floderus Y; Harper P; Yan J; Hagstrom H; Sardh E; Wahlin S
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(6):824-836
Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals
Lissing M; Vassiliou D; Floderus Y; Harper P; Bottai M; Kotopouli M; Hagstrom H; Sardh E; Wahlin S
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(1):81-94
Acute hepatic porphyria and maternal health: Clinical and biochemical follow-up of 44 pregnancies
Vassiliou D; Sardh E
Article: LIVER INTERNATIONAL. 2022;42(1):161-172
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study
Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiro P; Bissell DM; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2021;110(5):1250-1260
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver
Vassiliou D; Sardh E; Harper P; Simon AR; Clausen VA; Najafian N; Robbie GJ; Agarwal S
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2021;100(9):1712-1721
Treatment with assisted reproduction technologies in women with acute hepatic porphyria
Vassiliou D; Hirschberg AL; Sardh E
Article: GENOME MEDICINE. 2021;13(1):40
Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients
Stranneheim H; Lagerstedt-Robinson K; Magnusson M; Kvarnung M; Nilsson D; Lesko N; Engvall M; Anderlid B-M; Arnell H; Johansson CB; Barbaro M; Bjorck E; Bruhn H; Eisfeldt J; Freyer C; Grigelioniene G; Gustavsson P; Hammarsjo A; Hellstrom-Pigg M; Iwarsson E; Jemt A; Laaksonen M; Enoksson SL; Malmgren H; Naess K; Nordenskjold M; Oscarson M; Pettersson M; Rasi C; Rosenbaum A; Sahlin E; Sardh E; Stodberg T; Tesi B; Tham E; Thonberg H; Tohonen V; von Dobeln U; Vassiliou D; Vonlanthen S; Wikstrom A-C; Wincent J; Winqvist O; Wredenberg A; Ygberg S; Zetterstrom RH; Marits P; Soller MJ; Nordgren A; Wirta V; Lindstrand A; Wedell A
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(24):2289-2301
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani M; Sardh E; Ventura P; Peiro PA; Rees DC; Stoelzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang J-D; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L
Article: HEPATOLOGY. 2020;71(5):1546-1558
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
Gouya L; Ventura P; Balwani M; Bissell DM; Rees DC; Stoelzel U; Phillips JD; Kauppinen R; Langendonk JG; Desnick RJ; Deybach J-C; Bonkovsky HL; Parker C; Naik H; Badminton M; Stein PE; Minder E; Windyga J; Bruha R; Cappellini MD; Sardh E; Harper P; Sandberg S; Aarsand AK; Andersen J; Alegre F; Ivanova A; Talbi N; Chan A; Querbes W; Ko J; Penz C; Liu S; Lin T; Simon A; Anderson KE
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2019;380(6):549-558
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
Article: JOURNAL OF INTERNAL MEDICINE. 2018;284(1):78-91
Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver
Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec J-Y; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach J-C; Puy H; Peoc'h K; Manceau H; Gouya L
Article: JOURNAL OF PROTEOMICS. 2015;127(Pt B):377-385
Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria
Serrano-Mendioroz I; Sampedro A; Isabel Mora M; Mauleon I; Segura V; Enriquez de Salamanca R; Harper P; Sardh E; Jose Corrales F; Fontanellas A
Article: JOURNAL OF INHERITED METABOLIC DISEASE. 2013;36(6):1063-1071
High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria
Sardh E; Wahlin S; Bjornstedt M; Harper P; Andersson DEH
Article: PLOS ONE. 2012;7(3):e32978
Renal Failure Affects the Enzymatic Activities of the Three First Steps in Hepatic Heme Biosynthesis in the Acute Intermittent Porphyria Mouse
Unzu C; Sampedro A; Sardh E; Mauleon I; Enriquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
Article: TRANSPLANT INTERNATIONAL. 2010;23(6):e18-e21
Combined liver and kidney transplantation in acute intermittent porphyria
Wahlin S; Harper P; Sardh E; Andersson C; Andersson DEH; Ericzon B-G
Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2009;20(2):201-207
Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks
Sardh E; Harper P; Andersson DEH; Floderus Y
Article: CELLULAR AND MOLECULAR BIOLOGY. 2009;55(1):66-71
PORPHYRIN PRECURSORS AND PORPHYRINS IN THREE PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA AND END-STAGE RENAL DISEASE UNDER DIFFERENT THERAPY REGIMES.
Sardh E; Andersson DEH; Henrichson A; Harper P
Article: CLINICAL PHARMACOKINETICS. 2007;46(4):335-349
Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion
Sardh E; Rejkjaer L; Andersson DEH; Harper P
Article: CLINICAL CHEMISTRY. 2006;52(4):701-707
Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion
Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DEH; Harper P
Article: INFLAMMATION. 2002;26(6):291-296
Modulation of plasma levels of soluble adhesion molecules and nitric oxide in healthy volunteers by exposure to swine dust
Kölbeck KG; Sardh E; Gyllenhammar H; Palmberg L; Larsson K; Palmblad J
Show more

All other publications

Editorial comment: CANCERS. 2023;15(3):795
Comment on Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review
Lissing M; Vassiliou D; Harper P; Sardh E; Wahlin S
Review: EXPERT REVIEW OF GASTROENTEROLOGY AND HEPATOLOGY. 2022;16(9):879-894
Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran
Ventura P; Sardh E; Longo N; Balwani M; Plutzky J; Gouya L; Phillips J; Rhyee S; Fanelli M-J; Sweetser MT; Petrides PE
Letter: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2022;112(1):24
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported
Bins S; Sardh E; Langendonk JG
Review: JOURNAL OF INTERNAL MEDICINE. 2022;291(5):593-610
RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria
Sardh E; Harper P
Letter: JOURNAL OF INTERNAL MEDICINE. 2021;290(4):928-930
Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase
Vassiliou D; Sardh E
Other: CLINICAL CASE REPORTS. 2020;8(12):2483-2487
Challenges in the management of acute intermittent porphyria with recurrent attacks during pregnancy: A case report
Vassiliou D; Lempessi C; Harper P; Sardh E
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2020;383(20):1989-1990
Givosiran for Acute Intermittent Porphyria REPLY
Balwani M; Sardh E; Gouya L
Review: EXPERT OPINION ON ORPHAN DRUGS. 2014;2(4):349-368
Management of acute intermittent porphyria
Harper P; Sardh E
Thesis / dissertation: 2008
Acute intermittent porphyria : studies of chronic disease, recombinant enzyme therapy and late complications
Sardh, Eliane

Employments

Affiliated to Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, 2023-2026

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 2008
University Medical Degree, Karolinska Institutet, 1995

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI